Glycine, N-[4-[[2-(1-pyrrolidinyl)-4-pyrimidinyl]amino]phenyl]-N-[(2,4,6-trimethylphenyl)sulfonyl]- manufacturers
- DDO-5936
-
- $31.00
-
2026-07-17
- CAS:2355377-13-6
- Purity: 99.81%
- Supply Ability: 10g
|
| | Glycine, N-[4-[[2-(1-pyrrolidinyl)-4-pyrimidinyl]amino]phenyl]-N-[(2,4,6-trimethylphenyl)sulfonyl]- Basic information |
| Product Name: | Glycine, N-[4-[[2-(1-pyrrolidinyl)-4-pyrimidinyl]amino]phenyl]-N-[(2,4,6-trimethylphenyl)sulfonyl]- | | Synonyms: | Glycine, N-[4-[[2-(1-pyrrolidinyl)-4-pyrimidinyl]amino]phenyl]-N-[(2,4,6-trimethylphenyl)sulfonyl]-;DDO-5936;Inhibitor,DDO-5936,DDO 5936,colorectal,specific,inhibit,Glu47,potent,DDO5936,HSP,Heat shock proteins,Hsp90,cancer;DDO-5936, 10 mM in DMSO;N-(Mesitylsulfonyl)-N-(4-((2-(pyrrolidin-1-yl)pyrimidin-4-yl)amino)phenyl)glycine | | CAS: | 2355377-13-6 | | MF: | C25H29N5O4S | | MW: | 495.59 | | EINECS: | | | Product Categories: | | | Mol File: | 2355377-13-6.mol | ![Glycine, N-[4-[[2-(1-pyrrolidinyl)-4-pyrimidinyl]amino]phenyl]-N-[(2,4,6-trimethylphenyl)sulfonyl]- Structure](CAS/20210305/GIF/2355377-13-6.gif) |
| | Glycine, N-[4-[[2-(1-pyrrolidinyl)-4-pyrimidinyl]amino]phenyl]-N-[(2,4,6-trimethylphenyl)sulfonyl]- Chemical Properties |
| Boiling point | 752.5±70.0 °C(Predicted) | | density | 1.361±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Acetonitrile: Slightly Soluble: 0.1-1 mg/ml Chloroform: Slightly Soluble: 0.1-1 mg/ml DMSO: Sparingly Soluble: 1-10 mg/ml | | form | Solid | | pka | 3.12±0.10(Predicted) | | color | White to yellow |
| | Glycine, N-[4-[[2-(1-pyrrolidinyl)-4-pyrimidinyl]amino]phenyl]-N-[(2,4,6-trimethylphenyl)sulfonyl]- Usage And Synthesis |
| Uses | DDO-5936 is a potent and specific Hsp90-Cdc37 PPI inhibitor. DDO-5936 can be used for the research of colorectal cancer[1]. | | Biological Activity | DDO-5936 is a potent and specific Hsp90-Cdc37 PPI inhibitor. DDO-5936 can be used for the research of colorectal cancer[1].
DDO-5936 is a Hsp90-Cdc37 PPI inhibitor with potency and specificity through binding to a critical site on Hsp90 involving Glu47[1].
DDO-5936 (0~80 mg/kg; p.o.) shows effect at the high dose group[1].DDO-5936 is well tolerated for the absence of serious weight loss. DDO-5936 high dose groups show that tumor cells in the xenografts decreased significantly. DDO-5936 shows limited oral efficiency[1]. | | in vivo | DDO-5936 (0~80 mg/kg; p.o.) shows effect at the high dose group[1].
DDO-5936 is well tolerated for the absence of serious weight loss. DDO-5936 high dose groups show that tumor cells in the xenografts decreased significantly. DDO-5936 shows limited oral efficiency[1]. | Animal Model: | Mice[1] | | Dosage: | 0~80 mg/kg | | Administration: | P.o. | | Result: | Showed a moderate effect at the high dose group.
|
| | References | [1] Wang L, et al. Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer. J Med Chem. 2020;63(3):1281-1297. [2] LEI WANG. Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer[J]. Science Advances, 2019, 5 9. DOI: 10.1126/sciadv.aax2277 |
| | Glycine, N-[4-[[2-(1-pyrrolidinyl)-4-pyrimidinyl]amino]phenyl]-N-[(2,4,6-trimethylphenyl)sulfonyl]- Preparation Products And Raw materials |
|